Your browser doesn't support javascript.
loading
Micellar Curcumin: Pharmacokinetics and Effects on Inflammation Markers and PCSK-9 Concentrations in Healthy Subjects in a Double-Blind, Randomized, Active-Controlled, Crossover Trial.
Grafeneder, Juergen; Derhaschnig, Ulla; Eskandary, Farsad; Buchtele, Nina; Sus, Nadine; Frank, Jan; Jilma, Bernd; Schoergenhofer, Christian.
Afiliación
  • Grafeneder J; Department of Emergency Medicine, Medical University of Vienna, Vienna, 1090, Austria.
  • Derhaschnig U; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, 1090, Austria.
  • Eskandary F; Division of Nephrology, Department of Medicine III, Medical University of Vienna, Vienna, 1090, Austria.
  • Buchtele N; Department of Medicine I, Medical University of Vienna, Vienna, 1090, Austria.
  • Sus N; Department of Food Biofunctionality (140b), Institute of Nutritional Sciences, University of Hohenheim, Stuttgart, Germany.
  • Frank J; Department of Food Biofunctionality (140b), Institute of Nutritional Sciences, University of Hohenheim, Stuttgart, Germany.
  • Jilma B; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, 1090, Austria.
  • Schoergenhofer C; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, 1090, Austria.
Mol Nutr Food Res ; 66(22): e2200139, 2022 11.
Article en En | MEDLINE | ID: mdl-36101515
SCOPE: Preclinical models have demonstrated the anti-inflammatory and lipid-lowering effects of curcumin. Innovative formulations have been developed to overcome the poor bioavailability of native curcumin. The study hypothesizes that the bioavailability of micellar curcumin is superior to native curcumin and investigates the potential anti-inflammatory and proprotein convertase subtilisin/kexin type 9 (PCSK9) concentration lowering effects. METHODS AND RESULTS: In this double-blind, randomized, crossover trial, 15 healthy volunteers receive micellar or native curcumin (105 mg day-1 ) for 7 days with a ≥7 days washout period. Curcumin and metabolite concentrations are quantified by high-performance liquid chromatography with fluorescence detection (HPLC-FD), and pharmacokinetics are calculated. To analyze anti-inflammatory effects, blood samples (baseline, 2 h, 7 days) are stimulated with 50 ng mL-1 lipopolysaccharides (LPS). Interleukin (IL)-6, tumor-necrosis factor (TNF-α), and PCSK9 concentrations are quantified. Micellar curcumin demonstrates improved bioavailability (≈39-fold higher maximum concentrations, ≈14-fold higher area-under-the-time-concentration curve, p < 0.001) but does not reduce pro-inflammatory cytokines in the chosen model. Subjects receiving micellar curcumin have significantly lower PCSK9 concentrations (≈10% reduction) after 7 days compared to baseline (p = 0.038). CONCLUSION: Micellar curcumin demonstrates an improved oral bioavailability but does not show anti-inflammatory effects in this model. Potential effects on PCSK9 concentrations warrant further investigation.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Curcumina / Proproteína Convertasa 9 Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Mol Nutr Food Res Asunto de la revista: CIENCIAS DA NUTRICAO Año: 2022 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Curcumina / Proproteína Convertasa 9 Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Mol Nutr Food Res Asunto de la revista: CIENCIAS DA NUTRICAO Año: 2022 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Alemania